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Bioluminescent imaging (BLI) technology is a powerful tool for monitoring infectious dis-
ease progression and treatment approaches. BLI is particularly useful for tracking fastidious
intracellular pathogens that might be difﬁcult to recover from certain organs. Burkholderia
mallei, the causative agent of glanders, is a facultative intracellular pathogen and has been
classiﬁed by the CDC as a Category B select agent due to its highly infectious nature and
potential use as a biological weapon. Very little is known regarding pathogenesis or treat-
ment of glanders.We investigated the use of bioluminescent reporter constructs tomonitor
the dynamics of infection as well as the efﬁcacy of therapeutics for B. mallei in real-time. A
stable luminescent reporter B. mallei strain was created using the pUTmini-Tn5 ::luxKm2
plasmid and used to monitor glanders in the BALB/c murine model. Mice were infected via
the intranasal route with 5× 103 bacteria and monitored by BLI at 24, 48, and 72 h.We veri-
ﬁed that our reporter construct maintained similar virulence and growth kinetics compared
to wild-type B. mallei and conﬁrmed that it maintains luminescent stability in the presence
or absence of antibiotic selection. The luminescent signal was initially seen in the lungs,
and progressed to the liver and spleen over the course of infection. We demonstrated
that antibiotic treatment 24 h post-infection resulted in reduction of bioluminescence that
can be attributed to decreased bacterial burden in target organs. These ﬁndings suggest
that BLI can be used to monitor disease progression and efﬁcacy of therapeutics during
glanders infections. Finally, we report an alternative method to mini-Tn5 ::luxKm2 transpo-
son using mini-Tn7 -lux elements that insert site-speciﬁcally at known genomic attachment
sites and that can also be used to tag bacteria.
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INTRODUCTION
Burkholderia mallei are Gram negative, facultative intracellular
bacteria, and the causative agent for glanders. Horses, mules, and
donkeys are the only known natural reservoirs. The disease has
been eradicated in the United States, although it remains endemic
in the Middle East, Central and South America, and Asia. Among
humans, glanders is considered an occupational disease as most
individuals who contract the disease are lab workers (Srinivasan
et al., 2001) or individuals who come into close contact with
infected animals (Sanford, 1995). Typically, human infections
occur via contamination of the mucus membranes, wounds or
abrasions. B. mallei is highly infectious in aerosol form, requiring
very few organisms to establish an infection (Lever et al., 2003).
B. mallei is also regarded as a potential biological threat due to
their highly infectious nature and the incapacitating, often fatal
disease progression in humans. Despite the history of B. mallei as
a bio-weapon (Sharrer, 1995; Christopher et al., 1997), little data
about the efﬁcacy of vaccinations or antibiotic treatment methods
is available. Currently there are no vaccines available for either
equine or human B. mallei infections. Numerous reports indi-
cate in vitro susceptibility to a wide array of antibiotics (Kenny
et al., 1999; Heine et al., 2001; Judy et al., 2009) including: amino-
glycosides, cephalosporins, sulfonamides, macrolides, and ﬂuoro-
quinolones; however, the in vivo efﬁcacies are not well known.
Due to the potential use as a biological weapon and the scarcity of
in vivo treatment data, further evaluation of glanders progression
in response to antibiotic challenge and/or vaccination is of utmost
importance.
Bioluminescence imaging (BLI) is a technique based on the
detection of visible light produced by luciferase-catalyzed reac-
tions with a speciﬁc substrate. There are a variety of biolumines-
cent systems that have been identiﬁed in nature. The application
of these as reporter systems can be divided into two strategies.
The ﬁrst one centers on the use of luciferase enzymes alone.
Mammalian cells, or bacteria, can be engineered to express a
plasmid-borne copy of the luciferase enzyme fromorganisms such
as the ﬁreﬂy (Photinus pyralis) or the sea pansy (Renilla reni-
formis). Mammalian cells lack the required luciferin substrate for
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the bioluminescent reaction; therefore itmust be exogenously sup-
plied. The second strategy involves the use of the entire lux operon
from a bacterium such as Photorhabdus luminescens (formerly
Xenorhabdus luminescens). A transposon insertion or plasmid vec-
tor containing the luciferase enzyme, as well as the components for
substrate production can be engineered with a transposon inser-
tion (Flentie et al., 2008). This systemwill emit light in the range of
495–500 nm. Since the enzyme and substrate are both synthesized,
exogenous application of substrate is not necessary. The plasmid
vectors or transposon insertions confer a constitutively expressed
luminescent phenotype in a bacterial pathogen and permit the
real-time in vivo monitoring of the organism. BLI has routinely
beenutilized to trackdisease progression inmice.Salmonella enter-
ica serovar Typhimurium was transformed with the lux operon to
determine virulence differences between three strains in one of
the initial BLI studies on bacterial pathogenesis (Contag et al.,
1995). BLI has since been used to monitor bacterial dissemination
or to validate antimicrobial treatment regimen in Escherichia coli
(Rocchetta et al., 2001; Foucault et al., 2010) and Mycobacterium
tuberculosis (Andreu et al., 2010), as well as the select agents Fran-
cisella tularensis (Bina et al., 2010) and Burkholderia pseudomallei
(Owen et al., 2009). Since bioluminescence is related to bacte-
rial load, this property can be used to quantitatively assess the
pathogen burden as well as to provide new insights into tissue
tropism during infection (Hutchens and Luker, 2007).
Murine glanders has been widely used to study B. mallei infec-
tions and potential therapeutics (Leakey et al., 1998; Fritz et al.,
2000; Lever et al., 2003; Whitlock et al., 2008; Sarkar-Tyson et al.,
2009). BALB/c mice are highly susceptible to B. mallei infection
and provide an excellent model for acute glanders. C57BL/6 mice
are more resistant to infection and are better suited for model-
ing chronic glanders. In this study, we monitored the bacterial
infection in BALB/c mice with a strain of B. mallei containing
a stable, chromosomally integrated copy of the lux operon from
P. luminescens. After intranasal (i.n.) infection, the signal inten-
sity associated with the bioluminescent bacteria increased over
time in the lung as the bacteria replicated. Intraperitoneal antibi-
otic treatment correlated with decrease in bioluminescence, and
the infection re-emerged after antibiotic treatment was stopped.




Escherichia coli S17-1 (λpir) was used a host for the pUTmini-
Tn5::luxKm2 transfer plasmid described by Winson et al. (1998).
The plasmid wasmaintained in E. coli S17-1 (λpir) and wasmobi-
lized via conjugation into B. mallei ATCC 23344. For conjugation,
E. coli S17-1 (λpir) harboring the transfer plasmid and B. mallei
ATCC 23344 were grown overnight at 37˚C in 5ml Luria-Bertani
(LB) media (the E. coli cultures was supplemented with 50μg/ml
kanamycin). One milliliter of each overnight culture was pelleted
and washed with 1ml LB. Each culture was pelleted again and re-
suspended in 500μl of LB. The two cultures were combined and
passed through a 0.45-μM analytical ﬁlter. The ﬁlter was placed
on an LB plate, which was incubated for 6 h at 37˚C. The cells were
scraped from the surface of the ﬁlter and re-suspended in 3ml of
phosphate buffered saline (PBS). Dilutions were spread onto LB
plates supplemented with 4% glycerol (LBG) as well as 50μg/ml
kanamycin (Km) and 50μg/ml polymyxin B. These plates were
then incubated at 37˚C for 24 h.
Bioluminescent colonies from the B. mallei lux strain, hence-
forth referred to as CSM001, were detected by an in vitro imaging
system (IVIS) and were maintained on LBG plates with Km. B.
mallei strain ATCC 23344 was cultured on LBG for 48 h at 37˚C.
The isolated colonies were cultured in LBG broth shaking for 24 h
at 37˚C. Optical density readings (OD600) were used to determine
bacterial concentrations (CFU/ml). Bacteria were pelleted by cen-
trifugation and re-suspended in LBG broth to obtain the desired
concentration for inoculation.
Established protocols were used for isolation of biolumines-
cent B. thailandensis (Choi et al., 2005) and B. pseudomallei
(Choi et al., 2005). Brieﬂy, pUC18T-mini-Tn7T-Zeo-P1-lux was
introduced in B. thailandensis strain E264R [a rifampicin resis-
tant derivative of E264 (Choi et al., 2005)] by biparental mating
using E. coli mobilizer strain SM10 (λpir) and helper plasmid
pTNS3 (Choi et al., 2008). Exconjugants were selected on Lennox
LB medium (MO BIO Laboratories, Carlsbad, CA, USA) with
200μg/ml zeocin (Invitrogen, Carlsbad, CA, USA) and 200μg/ml
rifampicin (Sigma, St. Louis, MO, USA). The pUC18T-mini-
Tn7T-Gm-lux constructs, where the lux operon is expressed from
endogenous promoters, were transferred to B. pseudomallei strain
Bp340 (Mima and Schweizer, 2010) using biparental mating with
E. coli mobilizer strain RHO3 (Lopez et al., 2009). Exconjugants
were selected on LB Lennox medium with 15μg/ml gentamicin
(Sigma). The mini-Tn7 insertion sites were determined using
colony PCR and previously described protocols (Choi et al., 2005,
2008). pUC18T-mini-Tn7T-Zeo-P1-lux is based on pUC18T-
mini-Tn7T (Choi et al., 2006) and contains a zeocin resistance
selection marker and the P. xenorhabdus luxCDABE operon from
which internal restriction sites were removed (Voisey andMarincs,
1998). The lux operon on this plasmid is expressed from the P1
integron promoter (DeShazer and Woods, 1996).
All experiments conducted with B. mallei or B. pseudoma-
llei were conducted using Select Agent compliant BSL-3/ABSL-3
containment and procedures.
MICE
Female, 6- to 8-week-old,BALB/cmicewere obtained fromHarlan
(Indianapolis, IN, USA). Animal studies were performed in accor-
dance with the Institutional Animal Care and Use Committee’s
guidelines at UTMB as recommended by the National Institute of
Health.
IN VITRO STABILITY
The stability of the mini-Tn5::luxKm2 transposon insertion in
B. mallei was assessed by sub-culturing the CSM001 strain every
24 h over a period of 4 days as previously described (Foucault et al.,
2010). Brieﬂy,CSM001was grown for 48 h onLBGagar plates. Iso-
lated colonies were cultured in LBG broth shaking for 24 h at 37˚C.
The overnight culture was diluted 1:1000 in LBG broth in the pres-
ence or absence of antibiotic and incubatedwith shaking for 24 h at
37˚C. Cells from the culture were plated on LBG plates in the pres-
ence and absence of antibiotic and incubated for 24–48 h at 37˚C.
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The plateswere screened for bioluminescence and quantiﬁed using
the IVIS Spectrum imaging system (Caliper Corp., Alameda, CA,
USA). Each colony from the patch plate was selected as a region
of interest (ROI). The Caliper Life Sciences software quantiﬁed
the signal intensity for each ROI and an average intensity for each
plate was calculated.
GROWTH CURVE
The growth curve for CSM001 (log10 CFU/ml) was performed
in LBG broth and compared to the growth of wild-type B. mallei
ATCC23344 in three independent experiments. Samplingwas per-
formed at approximately 4 h intervals of the assay, from 0 to 16 h,
then at 26 and 38 h from the start of the experiment. The growth of
B. mallei wild-type and CSM001 strains were monitored by plat-
ing serial dilutions from the time points on LBG media as well as
by OD600 readings. Statistical differences were determined using
an unpaired t test with the signiﬁcance set at P< 0.05. The error
bars represent the SEM.
DETERMINATION OF LD50
Groups of 10 animals were i.n. inoculated with 102, 103, 104,
or 105 CFUs of CSM001 in a total volume of 50μl LB broth
(25μl/nare). Deaths were recorded over a period of 10 days. The
LD50 was calculated (Reed and Muench, 1938) based on the
dosages of the inocula.
BACTERIAL CHALLENGE AND ANTIBIOTIC TREATMENT
For the BLI experiments, animals were i.n. inoculated with
5× 103 CFUs of CSM001, unless otherwise indicated, in a total
volume of 50μl of LB broth (25μl/nare). Treatment with lev-
oﬂoxacin via the intraperitoneal (i.p.) route started 24 h after
infection, once a day, up to 96 h. Levoﬂoxacin (Levaquin Injection,
GlaxoSmithKline) was purchased from the UTMB Pharmacy and
prepared according to the manufacturer’s instructions at a dosage
of 20mg/kg/day.
BACTERIAL COLONIZATION
CSM001 was grown on LBG plates for 48 h at 37˚C followed by
sub-culturing in LBG broth shaking for 24 h at 37˚C. The bacterial
culture was diluted to a concentration of 5× 103 CFU per 50μl
(unless otherwise indicated). BALB/c mice were i.n. inoculated
with the prepared dosage (25μl/nare). Animals were imaged and
sacriﬁced at 24, 48, and 72 h post inoculation. The lungs, spleen,
and liver (when indicated) were harvested. Bioluminescent signal
was analyzed in the intact, extracted organs.
BIOLUMINESCENCE QUANTIFICATION
Bioluminescent images were acquired using an IVIS Spectrum
(Caliper Corp., Alameda, CA, USA). This system consists of a
heated stage inside a light–tight imaging chamber, a cooled charge-
coupled-device camerawith controller and refrigerationunit, inte-
grated anesthesia system,and aWindows computer system for data
acquisition and management. Bioluminescent signal was mea-
sured with no excitation (ﬁlters blocked) and an open emission
ﬁlter.
In preparation for in vivo imaging, anesthesia was induced
in the mice with 2–3% isoﬂurane in an oxygen-ﬁlled induction
chamber. Once anesthetized, the mice were transferred to an iso-
lation chamber, which was then placed in the imaging chamber
and connected to the in-chamber anesthesia delivery system and
maintained at 1–2% isoﬂurane. The ex vivo images of the lungs,
spleen, and liver were acquired at each time point immediately
after euthanasia. The organs were placed in a petri dish, and then
contained in the isolation chamber (during imaging). Biolumi-
nescent signal is represented in the images with a pseudocolor
scale ranging from red (most intense) to violet (least intense)
indicating the intensity of the signal. Scales were manually set
to the same values for every comparable image (in vivo and ex
vivo) to normalize the intensity of the bioluminescence across
time points.
RESULTS
ANALYSIS OF THE CSM001 REPORTER STRAIN
The CSM001 strain, a construct expressing the entire lux operon
was used to avoid the exogenous addition of luciferase substrate.
As a ﬁrst step toward evaluating the use of bioluminescence
for monitoring glanders, we wanted to ensure that the transpo-
son integration was stable by utilizing an in vitro stability assay
(Figure 1). CSM001 was grown in LBG and sub-cultured daily
over a period of 4 days in the appropriate media. Bacteria were
grown in the presence or absence of antibiotic to ensure that selec-
tion was not necessary to maintain the transposon stability. Every
FIGURE 1 | Stability assessment of mini-Tn5::luxKm2. (A)The stability of the mini-Tn5::luxKm2 transposon insertion in CSM001was assessed by
sub-culturing bacteria daily over 4 days in the presence and absence of antibiotic. (B) Each colony was selected as a region of interest and quantiﬁed using the
Living Image software. Insertion stability is expressed as the average radiance units (p/sec/cm2/sr)±SEM from three independent experiments.
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24 h, bacteria from the subculture were plated on the appropri-
ate media, incubated at 37˚C and monitored for bioluminescence.
The bacteria did not exhibit any apparent difference in the bio-
luminescent signal on the patch plates (Figure 1A) following
imaging. There was no signiﬁcant decrease in the luminescent
intensity over the 96-h time course (Figure 1B). The CSM001
strain sub-cultured in the presence of antibiotic exhibited the
same level of luminescence as those sub-cultured in the absence of
antibiotic.
Growth kinetic experiments were performed to ensure that B.
mallei strain CSM001 grows comparably to the parental B. mallei
ATCC 23344 strain. First we examined the virulence of ourmutant
strain compared to the wild-type strain (Figure 2A). Four groups
of 10 animals were i.n. inoculated with 102–105 CFUs of bac-
teria and monitored for survival over the 10-day time period.
Following the Reed and Muench method (Reed and Muench,
1938), the 10-day LD50 value was calculated to be 6.81× 102 CFU.
Next, we monitored the in vitro growth rate of the mutant strain
compared to the wild-type strain (Figure 2B). Brieﬂy, bacterial
cultures were grown in LBG media over 38 h. At the indicated
time points the OD600 was determined and dilutions of the cul-
ture were grown on LBG plates. The growth curves indicate
that the growth between the wild-type bacteria and the mutant
strain is comparable and not signiﬁcantly different throughout
the time points within the exponential growth phase (4–16 h)
stage.
IN VIVO BIOLUMINESCENCE IMAGING
Initial experiments were conducted to determine the threshold
detection limits of the CSM001 strain. Groups of mice were i.n.
infected with concentrations of bacteria ranging from 102 to 106
and monitored for daily luminescence analysis. Animals inocu-
lated with the 102 and 103 doses of bacteria showed no apparent
signs of infection 5 days post inoculation. Although luminescence
was not detected in vivo following a 2-h incubation, a lumines-
cent signal was detected in the lungs of animals infected with
1× 106 bacteria as soon as 2 h post-infection, indicating a bacte-
rial threshold for detection (Figure 3). A number of the animals
infected at the higher doses exhibited luminescence signal asso-
ciated within the brain, and all of these animals expired within
48 h after infection. No luminescence was initially detected with
a dosage 5× 103 CFU (Figure 3) although the signal increased
over time and the animals survived past 72 h (data not shown).
We further tested whether the CSM001 strain could be used as
a reporter strain to follow glanders progression in the BALB/c
mouse model. Two groups of four BALB/c mice were infected i.n.
with 5× 103 CFUs of the CSM001 strain (Figure 4). One group
was anesthetized every 24 h and monitored for bioluminescence
signal using the IVIS system, collecting, and quantifying the pho-
tons emitted by CSM001 within the animals. One animal was
sacriﬁced every 24 h, and the lungs and spleen were harvested for
ex vivo imaging. Bioluminescence signal was absent at 24 h both
in vivo and ex vivo, but was clearly evident at the 48- and 72-h time
points. As predicted, the bioluminescent signal increased over the
course of the study (Figure 4).CFUdeterminations conﬁrmed that
the observed bioluminescent signal increase. The bacterial bur-
den within the lungs of untreated animals steadily increased from
FIGURE 2 | CSM001 comparison to B. mallei ATCC 23344. (A)The 10-day
LD50 for CSM001 was determined by infecting groups of 10 animals by i.n.
with the indicated doses and monitoring the death (squares) and survival
(triangles) of the animals. (B) Cultures of CSM001 (open symbols) and B.
mallei ATCC 23344 (closed symbols) were grown to mid log phase (∼12h)
while shaking at 37˚C. The cultures were diluted 1:100 and monitored by
OD600 (circles) and CFU plating (squares) for 38 h at approximately 4 h
intervals. Individual data points represent the CFU mean±SEM of three
independent experiments. *, P <0.05.
approximately 7.77× 105 at 24 h to 5.96× 106 at 48 h and then
to 3.17× 108 at 72 h (Figure 6A). When the animals were treated
with levoﬂoxacin, the bacterial burden in the lungswasmuch lower
5.64× 103 at 48 h and 1.59× 105 at 72 h (Figure 6A). The bacter-
ial burden within the spleen also increased over the course of the
infection from approximately 2.15× 104 at 24 h to 5.72× 104 at
48 h and then 2.96× 105 at 72 h (Figure 6B). Animals treated with
levoﬂoxacin also showed decreased bacterial burden in the spleen
with 6.63× 102 CFU/organ at 48 h and 1.91× 104 CFU/organ at
72 h (Figure 6B).
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FIGURE 3 | In vivo imaging conﬁrmation. CSM001 was i.n. inoculated at
the indicated doses.The in vivo bioluminescence imaging was performed at
2 h post-infection.The intensity of emission is represented as a pseudocolor
image. Each animal was sacriﬁced and the lungs were harvested for ex vivo
imaging. Images are representative of replicate experiments.
Our previous studies with the BALB/c mouse model have
demonstrated thatB.mallei is sensitive to levoﬂoxacin both in vitro
and in vivo (Judy et al., 2009). It was shown that treatment
with levoﬂoxacin decreased the bacterial burden in the lung and
spleen of infected animals. Based on this evidence, we investigated
whether the decrease in bacterial burden conferred by levoﬂoxacin
treatment could be detected with our bioluminescence system.
A second group of animals (Figure 5A) received 20mg/kg/day
of levoﬂoxacin 24 h after infection. Every 24 h, the animals were
anesthetized and monitored for bioluminescence signal. One ani-
mal was sacriﬁced for ex vivo imaging of the lung and spleen, as
well as for CFU determination of those organs (data not shown).
The levoﬂoxacin treatment resulted in decreased bioluminescence
signal over the course of the infection. At the 48-h time point,
no signal can be detected in vivo or ex vivo although bacteria
were recovered following organ plating (data not shown). A sig-
nal does appear following imaging at 72 h in both the ex vivo and
in vivo images, however compared to the untreated animal the sig-
nal intensity is drastically reduced. This observation is consistent
with our previous studies, as levoﬂoxacin does not result in clear-
ance of the bacterial infection. In the levoﬂoxacin-treated animals,
the antibiotic was discontinued after 96 h. These animals were
imaged every 24 huntil a bioluminescence signalwas detected. The
re-emergence of signal occurred at 192 h and revealed apparent
bacterial colonization in the brain (Figure 5B).
CONSTRUCTION OF STABLE BIOLUMINESCENT BURKHOLDERIA
STRAINS USING MINI-Tn7 TRANSPOSONS
As an alternative to taggingwith randomly insertingmini-Tn5-lux
elements, we evaluated mini-Tn7 -lux elements (Figure 7A) that
insert site-speciﬁcally at known chromosomal attachment sites for
tagging of Burkholderia spp. To this end, mini-Tn7 -lux elements
were integrated into the genomes of B. thailandensis strain E264
and B. pseudomallei strain Bp340. The resulting strains emitted
light at levels that were comparable to those of B. mallei strain
ATCC 23344 tagged with a randomly inserted mini-Tn5-lux ele-
ment (Figure 1A). The levels of light emitted were somewhat
dependent on the promoter used for lux operon expression. For
example, the constitutive P1 integron promoter driving the dhfRII
gene from R388 encoding trimethoprim resistance is six times
more efﬁcient in E. coli than the de-repressed tac promoter (DeS-
hazer and Woods, 1996). Consequently, strong light emission was
observed in B. thailandensis expressing the lux operon from this
promoter (Figure 7B). By comparison, light emissionbyB. pseudo-
mallei where the lux operon is preceded by an∼500 bp DNA frag-
mentwhich contains at least ﬁvepredicted (BDGPNeuralNetwork
Promoter Prediction; www.fruitﬂy.org/seq_tools/promoter.html)
bacterial promoters with scores of 0.99 to 1.00 was still strong
(Figure 7C) but less intense than that observed with B. thailan-
densis with a mini-Tn7 -P1-lux element. Although several mini-
Tn7 -lux constructswith predicted strong promoterswere tested in
B. pseudomallei, cells containing the element with the ﬁve random
promoters consistently exhibited stable, strong light expression.
Promoter screening was by no means exhaustive and, for exam-
ple, did not include the ompA promoter that was previously used
to construct a mini-Tn7 -PompA-lux element that was success-
fully used to tag a B. pseudomallei strain and follow the disease
manifestation in a murine melioidosis model (Owen et al., 2009).
DISCUSSION
Burkholderia mallei is a Category B select agent that has been used
on a number of occasions as a biological weapon. Infection with B.
mallei can result in glanders, a disease that affects horses and other
equine species, developing into either an acute or chronic infec-
tion that ultimately leads to death. Glanders, while eradicated in
many countries, remains endemic in a number of areas across
the world. Despite the existence of endemic regions and poten-
tial threat of B. mallei as a bio-weapon, little data is available on
the efﬁcacy of glanders treatments. Therefore, there is an urgent
need for extensive evaluation of in vivo treatment methods. Data
collected by other groups has demonstrated that in vivo biolu-
minescence imaging is a valuable tool for providing insights into
the mechanisms of pathogenesis and disease progression, with the
goal of identifying new therapeutic approaches. In this study, we
demonstrate that glanders infection and treatment can be mon-
itored using CSM001, a bioluminescent reporter strain derived
from B. mallei ATCC 23344.
The CSM001 strain was created to monitor bacterial dissem-
ination by constitutive expression of the lux operon from P.
luminescens. The bacteria are constantly producing a lumines-
cent signal that can be correlated to bacterial burden in affected
organs. This simple and quantitative technique provides a number
of advantages over current approaches for monitoring bacterial
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FIGURE 4 | In vivo imaging of CSM001 infection. CSM001 was i.n.
inoculated into mice. The in vivo bioluminescence imaging was conducted at
24, 48, and 72 h post-infection. The intensity of emission is represented as a
pseudocolor image. At each time point, an animal was sacriﬁced and organs
were harvested for ex vivo imaging and bacterial load determination. Images
are representative of four replicate experiments.
dissemination and therapeutic efﬁcacies. Traditional methods for
determining bacterial localization, colonization, and bacterial bur-
den in vivo require that large numbers of experimental animals
be euthanized at various time points for assessment of individual
organs. Theuse of bioluminescence allows individual animals to be
analyzed at multiple time points. This reduces animal-to-animal
variation and ensures that biologically relevant information is not
overlooked. In the conventionalmethods of harvesting organs and
CFU plating, it is possible that the infection spreads to unexpected
sites and that these infected tissues are not collected. BLI permits
monitoring of the bacterial dissemination to these unexpected
infection sites. The preferential use of bioluminescent reporters
over ﬂuorescent constructs is primarily due to the fact that most
mammalian tissues are auto-ﬂuorescent at the same wavelengths
as the ﬂuorescent reporter constructs, resulting in a low signal to
noise ratio that is not observed when employing bioluminescent
reporters.
Bioluminescent imaging has been used to study the mecha-
nisms of pathogenesis and treatment efﬁcacies for a number of
infectious bacteria. One of the ﬁrst investigations using BLI was
conducted tomonitor the distribution and differences in virulence
among three strains of S. Typhimurium (Contag et al., 1995). In
this study, the authors demonstrated the utility of the biolumi-
nescence system by visualizing the efﬁcacy of antibiotic treatment
on infected animals. The in vivo bioluminescence has been uti-
lized to detect E. coli localization in the neutropenic mouse thigh
model where it was shown that bioluminescence was just as effec-
tive for determining antibiotic effectiveness as the traditional CFU
determinationmethods (Rocchetta et al., 2001). Also, biolumines-
cence in E. coli has been used to track bacterial colonization in the
mouse intestine (Foucault et al., 2010). BLI has also proven use-
ful for monitoring bacterial dissemination in a number of other
agents such as F. tularensis (Bina et al., 2010) and M. tuberculosis
(Andreu et al., 2010). Even the colonization routes of B. pseudo-
mallei, the closest relative of B. mallei, have been monitored using
a lux-tagged strain (Owen et al., 2009).
Because the lux operonwas inserted into the chromosome of B.
mallei via a transposon, it was important to ensure that insertion
did not occur in a site that disrupted the virulence or the rate of
growth of B. mallei. The LD50 assay and the growth curve analysis
demonstrated that our CSM001 strain mirrored the virulence and
growthkinetics of theB.malleiATCC23344wild-type strain. If the
transposon inserted into a site that increased virulence, it is possi-
ble that the infected mice would die prior to reaching a threshold
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FIGURE 5 | In vivo imaging of CSM001 infection post-antibiotic
treatment. (A) CSM001 was i.n. inoculated into mice. The in vivo
bioluminescence was monitored at 24, 48, and 72 h post-infection.
Treatment with 20mg/kg of levoﬂoxacin was administered after the
24-h time point. At each time point an animal was sacriﬁced and organs
were harvested for ex vivo imaging and bacterial load determination.
Images are representative of four replicate experiments. (B) Antibiotic
treatment was suspended following 96 h. Imaging was conducted
every 24 h until the luminescence signal returned (192 h time
point).
detection limit. It has been previously reported that the LD50 for
B. mallei ATCC 23344 ranges from 1.8× 103 (Lever et al., 2003)
to 2.5× 105 (Whitlock et al., 2009). We determined the LD50 for
the CSM001 strain to be 6.81× 102. Our present study focused on
the ability to create a bioluminescent B. mallei strain with similar
virulence and growth kinetics to the wild-type strain.
As an alternative to tagging with randomly inserting mini-
Tn5-lux transposons, mini-Tn7 -lux elements that insert site-
speciﬁcally at known chromosomal attachment sites can be used
to construct reporter bacteria. The attachment sites are generally
located in intergenic regions and thus integrants are less likely
to be attenuated. Mini-Tn7 elements offer the added advantage
that, unlike “locked in” mini-Tn5 insertions, they can be read-
ily inserted at the same site in mutant derivatives of the same
bacterial strain thereby allowing comparative analyses in isogenic
backgrounds. While mini-Tn7 -lux derivatives have been used
to construct bioluminescent B. pseudomallei and B. thailanden-
sis strains (Figure 7; Owen et al., 2009), they have not yet been
employed for construction of bioluminescent B. mallei. However,
this will be easy to achieve since detailed protocols for site- and
orientation-speciﬁc mini-Tn7 tagging of Burkholderia spp. have
been published, including B. thailandensis (Choi et al., 2005), B.
pseudomallei (Choi et al., 2008), and B. mallei (Choi et al., 2006).
While the P. luminescens wild-type luxCDABE operon seems to
be well expressed in Burkholderia spp., there is room for improve-
ment. Stable expression of the lux operon can be further optimized
by screening of additional promoters known to be well-tolerated
and constitutively expressed in Burkholderia spp., for example the
s12 ribosomal gene promoter (Choi et al., 2008) or the ompA gene
promoter (Owen et al., 2009). The P. luminescens wild-type lux-
CDABE operon is also very A+T rich (>69%) and it has been
proposed that for this and other reasons, e.g., rare codon usage,
these genes may not be expressed very well in bacteria with high
G+Ccontent genomes.Toovercome this potential hurdle,Craney
et al. (2007) derived a synthetic luxCDABE gene cluster optimized
for expression in bacteria with high G+C content. It may be
worthwhile considering engineering of mini-Tn7 -lux elements
that exhibit strong, yet stable, light emission using a combina-
tion of optimized genus- or species-speciﬁc promoter sequences
and a lux operon optimized for gene expression in bacteria with
high G+C content.
The in vivo BLI can be used to identify dissemination of bacte-
rial infections in the i.n. mouse model. The BALB/c mouse model
has routinely been used to study B. mallei infection, as it is highly
susceptible (Leakey et al., 1998; Fritz et al., 2000; Lever et al.,
2003; Whitlock et al., 2008; Sarkar-Tyson et al., 2009). We moni-
tored BALB/c mice that had been i.n. infected with the CSM001
strain. Over the course of the infection, the bacterial burden in the
target organs increased and the infection sites became lumines-
cent and visible with the IVIS. The data collected are consistent
with the traditionalmethods for characterizing bacterial infection.
Lever et al. (2003) demonstrated that following aerosol expo-
sure to B. mallei, bacterial counts are ﬁrst detected in the lungs
and steadily increased over 5 days, at which point the bacterial
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FIGURE 6 | B. mallei bacterial burden in treated and untreated
BABLB/c mice. CSM001 was i.n. inoculated into BALB/c mice as indicated
previously for the bioluminescent imaging. At each time point, untreated
(closed symbols) or treated (open symbols) animals with 20mg/kg/day of
levoﬂoxacin were sacriﬁced and the lungs (A) and spleen (B) were
harvested at 24 h (squares), 48 h (circles), 72 h (diamonds) and plated for
CFU determination.
burden decreases. We showed that after 24 h of infection there
is no bioluminescence signal in the lungs, despite the presence
of approximately 1× 106 bacteria. Presumably this is because a
threshold detection limit has not been reached as is evident in
Figure 3. After 48 h, the bioluminescence signal is visible and this
signal increases in intensity at 72 h (Figure 4).
Currently, there are no effective vaccines available for glanders
infection and very little data exists on the efﬁcacy of antibiotic
for treatment of human glanders. One case of human glanders
involving an accidental lab exposure was treated with a mixed
regimen of antibiotics (Srinivasan et al., 2001). A more standard-
ized course of treatment is necessary however, due to the fact that
FIGURE 7 | Bioluminescent tagging of Burkholderia spp. with mini-Tn
7-lux elements. (A) Map of a typical mini-Tn7 -lux element. The basic
element contains a promoter-less P. luminescens luxCDABE operon that is
preceded by a multiple cloning site (MCS). An antibiotic resistance (Abr)
selection marker inserted upstream of the lux operon is preferably ﬂanked
by yeast Flp recombinase target (FRT ) sites that allow optional site-speciﬁc
excision of the Abr marker after site-speciﬁc insertion into the bacterial
chromosome. Restriction sites in the MCS can also be used to insert
customized promoter sequences (arrow labeled P ). (B) A mini-Tn7 -lux
element with a zeocin resistance selection marker was inserted into the
glmS1-associated insertion site of chromosome 1 of B. thailandensis strain
E264 (Choi et al., 2005). Bacteria containing either no insertion (1), a
promoter-less mini-Tn7 -lux (2) or a mini-Tn7 -P1-lux element where the lux
operon is transcribed from the strong P1 integron promoter (DeShazer and
Woods, 1996) were grown overnight on an LB plate and imaged on an IVIS
Spectrum imaging system. (C) A mini-Tn7 -lux element with a gentamicin
resistance selection marker was inserted into the glmS3-associated
insertion site on chromosome 2 of B. pseudomallei strain Bp340 (Choi et al.,
2008; Mima and Schweizer, 2010). Bacteria containing either no insertion
(1) or a mini-Tn7 -lux element where the lux operon is transcribed from
synthetic promoter sequences active in B. pseudomallei (2) were grown
overnight on an LB plate and imaged on an IVIS Spectrum imaging system.
mixed antibiotic regimen must be administered for a number of
days and assumes an accurate and early diagnosis. The antibiotic
susceptibility of B. mallei is similar to that of B. pseudomallei and
because of this, most B. mallei antibiotic treatments are based
on efﬁcacy of treatment regimens for B. pseudomallei infections.
Levoﬂoxacin inhibits DNA replication and transcription in Gram
negative bacteria and has previously been shown to decrease bacte-
rial burden in the lung and spleen of BALB/c mice infected with B.
mallei (Judy et al., 2009). Here, we demonstrated that the decrease
in bacterial burden in the lungs can be visualized using BLI tech-
nology. Animals were treated with antibiotic 24 h post-infection,
and when the animals were imaged at 72 h, a luminescence signal
was visible, although the intensity was markedly reduced. Antibi-
otic efﬁcacy studies have revealed that B. mallei is susceptible to a
number of antibiotics in vitro, although in vivo analysis still needs
to be performed; therefore,BLI is a useful tool for assessing various
treatments using fewer animals. BLI should also prove useful for
monitoring novel therapeutic targets such as new antibiotics, quo-
rum sensingmolecules (reviewed in Estes et al., 2010) or virulence
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factors associated with the type three (Whitlock et al., 2007) and
type six secretion systems (Schell et al., 2007).
A number of our BLI experiments revealed bioluminescence
signal associated with the brain of the animals. It was previously
reported that the nasal-associated lymphoid tissue (NALT) of
BALB/c mice acts as an entryway for B. pseudomallei (Owen et al.,
2009). The authors concluded that the olfactory nerve served as a
route of entry for B. pseudomallei to the brain after i.n. infection
with 3.6× 105 CFU. The implication was alsomade that this route
of entry could be responsible for the infections of the CNS often
seen in human melioidosis (Currie et al., 2000; Chadwick et al.,
2002;White, 2003; Koszyca et al., 2004). Based on our observations
(Figure 5B), it is possible that B. mallei utilizes the same olfactory
nerve to reach the brain in mice. Owen et al. (2009) observed
localization of B. pseudomallei to the brain 48 h after infection.
Our experiments with B. mallei required at least 72 h before signal
could be detected. Further clariﬁcation of the role of NALT during
glanders infection could provide insights for future vaccination
therapies.
In summary, we have developed and validated a BLI tech-
nique for the detection of B. mallei infection in the BALB/c
intranasal model of acute glanders. We demonstrated that this
highly sensitive reporter strategy can be used to obtain in vivo
images of B. mallei infection in mice. This BLI method is straight-
forward and reduces the numbers of animals traditionally required
and can be useful for antibiotic efﬁcacy studies as shown by the
decrease in luminescent signal of levoﬂoxacin-treated animals.
Future studies will verify previously reported in vitro antibiotic
efﬁcacies and test vaccine candidates.
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